Medicare Enrolled

Dr. Uriel Sandkovsky, MD, MS

Internal Medicine · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
5200 HARRY HINES BLVD, Dallas, TX 75235
2145908000
In practice since 2009 (16 years)
NPI: 1104060904 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sandkovsky from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sandkovsky? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Sandkovsky

Dr. Uriel Sandkovsky is an internal medicine in Dallas, TX, with 16 years in practice. Based on federal Medicare data, Dr. Sandkovsky performed 17,158 Medicare services across 1,532 unique beneficiaries.

Between the years covered by Open Payments, Dr. Sandkovsky received a total of $290,387 from 42 pharmaceutical and/or device companies across 857 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Sandkovsky is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 16 years in practice▲ Top 2% volume in TX$ $290,387 industry payments

Medicare Practice Summary

Medicare Utilization ↗
17,158
Medicare services
Top 2% in TX for internal medicine
1,532
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,072 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Denosumab injection (Prolia/Xgeva)13,500$18$50
Hospital follow-up visit, high complexity1,103$93$289
Hospital follow-up visit, moderate complexity776$62$202
Office visit, established patient (30-39 min)420$79$279
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less339$50$394
Drug injection, under skin or into muscle289$10$59
Initial hospital admission, high complexity268$137$546
Injection, zoledronic acid, 1 mg190$6$41
Injection, ertapenem sodium, 500 mg75$10$79
Office visit, established patient (20-29 min)67$48$185
New patient office visit (45-59 min)40$113$425
Office visit, established patient, complex (40-54 min)25$130$377
Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow23$83$303
Initial hospital admission, moderate complexity22$103$372
Insertion of tube for infusion with imaging guidance and review by radiologist, patient 5 years or older21$283$1,225
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.1% high complexity
81.9% medium
16.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$290,387
Total received (2018-2024)
Avg $41,484/year across 7 years
Top 1% in TX for internal medicine
42
Companies
857
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$238,385 (82.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$40,889 (14.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,113 (3.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$108,914
2023
$87,011
2022
$41,707
2021
$21,619
2020
$12,855
2019
$17,507
2018
$774

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Shionogi Inc
$79,992
PFIZER INC.
$64,568
AIMMUNE THERAPEUTICS, INC.
$52,453
ViiV Healthcare Company
$40,528
Paratek Pharmaceuticals, Inc.
$36,813
TETRAPHASE PHARMACEUTICALS, INC.
$4,587
PFIZER INTERNATIONAL LLC
$3,500
Gilead Sciences, Inc.
$1,010
Insmed, Inc.
$961
Astellas Pharma US Inc
$799
Merck Sharp & Dohme LLC
$618
EMD Serono, Inc.
$538
Napo Pharmaceuticals Inc
$445
Novocure Inc.
$413
Janssen Biotech, Inc.
$337
Cumberland Pharmaceuticals, Inc.
$315
Saol Therapeutics Inc.
$290
ABBVIE INC.
$279
Merck Sharp & Dohme Corporation
$265
La Jolla Pharmaceutical Company
$192
Ferring Pharmaceuticals Inc.
$186
Theratechnologies Inc.
$156
Takeda Pharmaceuticals U.S.A., Inc.
$152
AbbVie Inc.
$140
Janssen Products, LP
$125
MAYNE PHARMA INC.
$104
Amgen Inc.
$96
Octapharma USA, Inc.
$82
Melinta Therapeutics, LLC
$73
Mayne Pharma Inc.
$56
HOSPIRA, INC.
$53
Allergan Inc.
$43
Melinta Therapeutics, Inc.
$30
VBI Vaccines (Delaware) Inc.
$29
KCI USA, Inc.
$26
Novartis Pharmaceuticals Corporation
$24
Eurofins Viracor, Inc.
$24
Amarin Pharma Inc.
$23
Grifols USA, LLC
$21
Genentech USA, Inc.
$19
Nabriva Therapeutics, plc
$11
Dynavax Technologies Corporation
$11
Top 3 companies account for 67.8% of total payments
Associated products mentioned in payments ›
ACTIMMUNE · AMBISOME · APRETUDE · AVYCAZ · Arikayce · Baxdela · Biktarvy · CABENUVA · CRESEMBA · Cresemba · DALVANCE · DELSTRIGO · DIFICID · DORYX · DOVATO · EGRIFTA · ELIQUIS · EVENITY · Fetroja · GATTEX · GIAPREZA · Heplisav-B · ISENTRESS · JULUCA · Kimyrsa · LIVTENCITY · MYCAMINE · Mytesi · NOXAFIL · NUZYRA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · PANZYGA · PAXLOVID · PIFELTRO · PREVENA · PREVNAR - 13 · PREVNAR 13 · PREVYMIS · PREZCOBIX · PreHevbrio · REBYOTA · RUKOBIA · Rezzayo · SEROSTIM · SYMTUZA · Serostim · Symtuza · TEFLARO · TIVICAY · TRIUMEQ · TROGARZO · VAC VERAFLO · VIBATIV · VOWST · Vabomere · Vascepa · Vibativ · XERAVA · Xembify · Xenleta · Xerava · Xofluza · ZENPEP · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in internal medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for internal medicine in TX.

Equivalent to $1,692 per 100 Medicare services performed
Looking for a internal medicine in Dallas?
Compare internal medicines in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse internal medicines nearby

Geographic Context

Internal Medicines within 10 mi
2,266
Per 100K population
87.0
County median income
$74,149
Nearest hospital
PARKLAND HEALTH & HOSPITAL SYSTEM
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Sandkovsky is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), and high industry engagement (speaking/promotional, top 1%), with 16 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Sandkovsky experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Sandkovsky performed 13,500 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sandkovsky receive payments from pharmaceutical companies?
Yes. Dr. Sandkovsky received a total of $290,387 from 42 companies across 857 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sandkovsky's costs compare to other internal medicines in Dallas?
Dr. Sandkovsky's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sandkovsky) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →